Reference drug substance used to treat toxoplasmosis and malaria.

Specification – pharmacopeia: USP, In-House

Therapeutic category: Antimalarial, dihydrofolate reductase inhibitor

Treatment: Pneumonia prophylaxis, Toxoplasmosis and malaria